SNPHF (Santen Pharmaceutical Co) Cyclically Adjusted FCF per Share: $0.46 (As of Mar. 2026)


SNPHF Santen Pharmaceutical Co Ltd SNPHF
83 GF Score
Price $13.05
GF Value $10.24
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Santen Pharmaceutical Co Cyclically Adjusted FCF per Share?

Santen Pharmaceutical Co SNPHF +4.40% 83 Cyclically Adjusted FCF per Share is $0.46 as of Mar. 2026. GuruFocus rates SNPHF with a GF Score™ of 83/100 and a GF Value™ of $10.24 (Modestly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Santen Pharmaceutical Co's adjusted free cash flow per share for the three months ended in Mar. 2026 was $0.354. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.46 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 31.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Santen Pharmaceutical Co was 31.00% per year. The lowest was -1.60% per year. And the median was 4.10% per year.

As of today (2026-07-07), Santen Pharmaceutical Co's current stock price is $13.05. Santen Pharmaceutical Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $0.46. Santen Pharmaceutical Co's Cyclically Adjusted Price-to-FCF of today is 28.37.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Santen Pharmaceutical Co was 76.54. The lowest was 20.13. And the median was 42.67.


Santen Pharmaceutical Co  (OTCPK:SNPHF) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Santen Pharmaceutical Co's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=13.05/0.46
=28.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Santen Pharmaceutical Co was 76.54. The lowest was 20.13. And the median was 42.67.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Santen Pharmaceutical Co Cyclically Adjusted FCF per Share Related Terms


Santen Pharmaceutical Co Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Santen Pharmaceutical Co's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santen Pharmaceutical Co Cyclically Adjusted FCF per Share Chart

Santen Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.29 0.25 0.27 0.00 0.46

Santen Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.49 0.47 0.40 0.46

SNPHF vs LLY, JNJ, ABBV: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santen Pharmaceutical Co Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Santen Pharmaceutical Co's Cyclically Adjusted Price-to-FCF falls into.


SNPHF
83GF Score
Santen Pharmaceutical Co Ltd SNPHF
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santen Pharmaceutical Co Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Santen Pharmaceutical Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.354/112.7000*112.7000
=0.354

Current CPI (Mar. 2026) = 112.7000.

Santen Pharmaceutical Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.417 98.100 -0.479
201609 0.198 98.000 0.228
201612 0.073 98.400 0.084
201703 0.169 98.100 0.194
201706 0.086 98.500 0.098
201709 0.307 98.800 0.350
201712 0.103 99.400 0.117
201803 0.240 99.200 0.273
201806 -0.106 99.200 -0.120
201809 0.402 99.900 0.454
201812 0.053 99.700 0.060
201903 0.189 99.700 0.214
201906 0.067 99.800 0.076
201909 0.378 100.100 0.426
201912 0.029 100.500 0.033
202003 0.239 100.300 0.269
202006 -0.021 99.900 -0.024
202009 0.149 99.900 0.168
202012 -0.060 99.300 -0.068
202103 0.278 99.900 0.314
202106 -0.050 99.500 -0.057
202109 0.335 100.100 0.377
202112 -0.042 100.100 -0.047
202203 -0.010 101.100 -0.011
202206 -0.072 101.800 -0.080
202209 0.115 103.100 0.126
202212 0.104 104.100 0.113
202303 0.094 104.400 0.101
202306 -0.007 105.200 -0.007
202309 0.429 106.200 0.455
202312 0.589 106.800 0.622
202403 0.171 107.200 0.180
202406 0.196 108.200 0.204
202409 0.250 108.900 0.259
202412 0.183 110.700 0.186
202503 0.000 111.100 0.000
202506 0.119 111.700 0.120
202509 -0.035 112.000 -0.035
202512 0.129 113.000 0.129
202603 0.354 112.700 0.354

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $0.46 mean?
Santen Pharmaceutical Co (SNPHF) has a Cyclically Adjusted FCF per Share of $0.46 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Santen Pharmaceutical Co and its competitors.
Is Santen Pharmaceutical Co's Cyclically Adjusted FCF per Share too high?
Santen Pharmaceutical Co's current Cyclically Adjusted FCF per Share is $0.46. Overall, Santen Pharmaceutical Co has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Cyclically Adjusted FCF per Share compare to LLY and JNJ?
Santen Pharmaceutical Co's Cyclically Adjusted FCF per Share of $0.46 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Santen Pharmaceutical Co and its competitors. Santen Pharmaceutical Co's current Cyclically Adjusted FCF per Share is $0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHF) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.24, compared to a current price of $13.05 — trading 27.4% above its estimated fair value. The current Cyclically Adjusted FCF per Share is $0.46. Santen Pharmaceutical Co's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHF), the current Cyclically Adjusted FCF per Share is $0.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santen Pharmaceutical Co (SNPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued. The current stock price of $13.05 is trading 27.4% above its estimated GF Value™ of $10.24. GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SNPHF:

  • Cyclically Adjusted FCF per Share: $0.46
  • GF Value™: $10.24 vs. price of $13.05 (27.4% above fair value)
  • GF Score™: 83/100 with 6 warning signs

No single metric tells the full story. See the SNPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Santen Pharmaceutical Co Business Description

Other Exchanges SNPHY:USA4536:Japan
Address 4-20 Ofukacho, Grand Front Osaka Tower A, Kita-ku, Osaka Prefecture, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
83GF Score

Get the complete analysis for SNPHF

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.05
Price
$10.24
GF Value